Pulse Biosciences (NASDAQ:PLSE) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a report released on Thursday.

Separately, BidaskClub raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, June 8th.

Shares of PLSE traded down $0.44 during trading hours on Thursday, reaching $13.69. 50,600 shares of the company traded hands, compared to its average volume of 110,066. Pulse Biosciences has a 1-year low of $10.31 and a 1-year high of $34.82.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Tuesday, July 31st. The company reported ($0.54) EPS for the quarter.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp raised its position in shares of Pulse Biosciences by 9.1% during the second quarter. Bank of New York Mellon Corp now owns 61,550 shares of the company’s stock valued at $932,000 after buying an additional 5,127 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Pulse Biosciences during the fourth quarter valued at about $290,000. Bank of America Corp DE raised its position in shares of Pulse Biosciences by 631.2% during the second quarter. Bank of America Corp DE now owns 16,101 shares of the company’s stock valued at $244,000 after buying an additional 13,899 shares during the last quarter. Silverleafe Capital Partners LLC acquired a new position in shares of Pulse Biosciences during the second quarter valued at about $500,000. Finally, BlackRock Inc. raised its position in shares of Pulse Biosciences by 23.0% during the second quarter. BlackRock Inc. now owns 600,109 shares of the company’s stock valued at $9,085,000 after buying an additional 112,061 shares during the last quarter. 9.84% of the stock is owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc, a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications.

Featured Article: What are Closed-End Mutual Funds?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.